Explore a selection of the 200+ articles we've published since our founding
Annals of Oncology (2016)
In this review, the role of somatic BRCA mutations and BRCA methylation in ovarian cancer is discussed alongside the challenges that need to be addressed if the full potential of these markers of HRD is to be utilised in clinical practice.
CD74-ROS1 fusion in NSCLC detected by hybrid capture-based tissue genomic profiling and ctDNA assays
Journal of Thoracic Oncology (2017)
A case study of a patient with metastatic NSCLC with a ROS1 fusion detected by tissue and blood hybrid capture–based assays but not by another circulating tumor DNA (ctDNA) assay.
Clinical Cancer Research (2017)
A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer.
Patient-derived xenotransplants (PDX) can recapitulate the genetic driver landscape of acute leukemias
Leukemia (January 2017)
These data emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.
Lung Cancer (September 2017)
This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.
Journal of Neuro-Oncology (2016)
Genomic research of high-grade glioma (HGG) has revealed complex biology with potential for therapeutic impact.
The Lancet Oncology (2016)
The ARIEL2 study assessed the ability of tumour genomic LOH, quantified with a next-generation sequencing assay, to predict response to rucaparib, an oral PARP inhibitor.
Journal of the National Comprehensive Cancer Network (February 2016)
This exceptional response to pazopanib treatment suggests that a subset of patients with angiosarcoma with genomic alterations in vascular signaling genes may respond well to pazopanib.
Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping
Journal of Thoracic Oncology (January 2017)
The full spectrum of resistance mechanisms to crizotinib in METex14-positive NSCLC remains to be identified. Noninvasive plasma-based ctDNA assays can provide a convenient method to detect resistance mutations in patients with previously known driver mutations.